CHAPTER 28 — REFERENCES


70. Hersey P, Soman J, O'Dwyer S, et al. A randomised phase 2 study of eta-


72. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus oxalipl-


74. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxalipl-


yses of the international randomized phase III CENTRIC trial (EORTC trial #20071-22072/Canadian Brain Tumor Consortium). Program and abstracts of the 10th European Cancer Congress; 2013; Amsterdam.


82. Brosé M, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or meta-


90. Kumar R, Knick-Y, Ruchala-SM, et al. Sorafenib treatment-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogen-

91. Sternberg CN, Davis ID, Mandlik J, et al. Pazopanib in locally advanced or meta-

92. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in meta-

93. van der Graaf WJ, Bay JT, Chauwa SP, et al. Pazopanib for metastatic soft-

94. Gaya A, Tse V. A preclinical and clinical review of axitinib for the manage-

95. van Coetem E, Talbotto R, Lambrino R, et al. Addition of aflibercept to fluo-
rouracil, leucovorin, and irinotecan improves survival in a phase III random-


98. Escudier B, Eisen T, Stadler WM, et al. Sorafenib treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approach-


100. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or meta-

123. Paz-Ríos M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malign-
125. South DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with ad-
131. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsi-
132. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as

---

Devita_References.indd   65
10/23/14 4:21 AM